The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

Tertiary lymphoid structures (TLSs) are defined as lymphoid aggregates formed in non-
hematopoietic organs under pathological conditions. Similar to secondary lymphoid organs …

Despite documented evidence that ovarian cancer cells express immune-checkpoint
molecules, such as PD-1 and PD-L1, and of a positive correlation between the presence of …

Tumor-associated tertiary lymphoid structures (TLS) have been associated with favorable
clinical outcomes and response to immune checkpoint inhibitors in many cancer types …

Background Tertiary lymphoid structures (TLSs) impact cancer outcomes, including in triple-
negative breast cancer (TNBC), where their role in immune modulation during neoadjuvant …

Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor response to all
therapeutic modalities and dismal prognosis. The presence of tertiary lymphoid structures …

The success of immunotherapy approaches, such as immune checkpoint blockade and
cellular immunotherapy with genetically modified lymphocytes, has firmly embedded the …

Genomic instability is a driver and accelerator of tumorigenesis and influences disease
outcomes across cancer types. Although genomic instability has been associated with …

Despite the remarkable clinical success of immune checkpoint blockade (ICB) in the
treatment of cancer, the response rate to ICB therapy remains suboptimal. Recent studies …

Tertiary lymphoid structures (TLS) can reflect cancer prognosis and clinical outcomes in
various tumour tissues. Tumour-associated macrophages (TAMs) are indispensable …